Trump Just Broke the Controlled Substances Act, But There's a Chance to Fix It

Healthcare & Life Sciences attorney Sara Klock was mentioned in a Cannabis Equipment News article about how the rescheduling of medical use cannabis affects the broader cannabis industry. In particular, the article focused on the new split between classification of medical marijuana – Schedule III – and recreational marijuana – Schedule I – under the Controlled Substances Act. Although the change is welcome news for cannabinoid researchers and companies selling products approved for medical use, Ms. Klock pointed out it also creates uncertainty for hybrid operators and state regulators. It's not clear, she said, how states should go about reviewing safety and labeling of these products or whether manufacturers will need to adjust their processes to conform to the new placement.

READ: Trump Just Broke the Controlled Substances Act, But There's a Chance to Fix It